μ-receptor agonism with alfentanil increases striatal dopamine D2 receptor binding in man

Synapse

Volumn 45, Issue 1, 2002, Pages 25-30

  Hagelberg, Nora ^a   Kajander, Jaana K ^b   Någren, Kjell ^c   Hinkka, Susanna ^b   Hietala, Jarmo ^a,c   Scheinin, Harry ^b,c  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c TURKU PET CENTRE   (Finland)

Author keywords

opioid; Dopamine D2 receptor; PET; Raclopride

Indexed keywords

ALFENTANIL; DOPAMINE 2 RECEPTOR; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; RACLOPRIDE; RADIOLIGAND;

ADULT; ARTICLE; BREATHING RATE; CAUDATE NUCLEUS; CEREBELLUM; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG RECEPTOR BINDING; END TIDAL CARBON DIOXIDE TENSION; HUMAN; HUMAN EXPERIMENT; MALE; NEUROTRANSMISSION; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN SATURATION; PAIN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; VISUAL ANALOG SCALE;

ADULT; ALFENTANIL; ANALGESICS, OPIOID; BRAIN; CAUDATE NUCLEUS; CEREBELLUM; CORPUS STRIATUM; DOPAMINE ANTAGONISTS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PUTAMEN; RACLOPRIDE; RECEPTORS, DOPAMINE D2; RECEPTORS, OPIOID, MU; REFERENCE VALUES; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036266939     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.10078     Document Type: Article

References (31)

1. Changes in brain monoamine metabolism during withdrawal from chronic oral self-administration of morphine and in response to a morphine challenge in the withdrawn state
2. Augmentation of morphine-induced changes in brain monoamine metabolism after chronic naltrexone treatment
3. 3H]spiperone binding to the guinea-pig striatum: Autoradiographic evidence
4. Effect of amphetamine on extrastriatal D2 dopamine receptor binding in the primate brain: A PET study
5. Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: In vivo microdialysis studies
6. 11C-raclopride is altered by drugs that modify synaptic dopamine levels
7. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats
8. 2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography
9. 11C]-raclopride in vivo: A test-retest analysis
10. Ventilator effects of clonidine alone and in the presence of alfentanil, in human volunteers
11. Opioids excite dopamine neurons by hyperpolarization of local interneurons
12. Different patterns of hyperalgesia induced by experimental inflammation in human skin
13. Inflammatory models of cutaneous hyperalgesia are sensitive to effects of ibuprofen in man
14. Simplified reference tissue model for PET receptor studies
15. 11C-methyl]-(-)-cocaine PET studies in human subjects
16. 11C]raclopride binding in the brain: Model simulations and kinetic analysis of PET data
17. Distribution volume ratios without blood sampling from graphical analysis of PET data
18. Increased sensitivity to dopamine agonists following a single dose of morphine or levorphanol in mice
19. Radioimmunoassay of the new opiate analgesic alfentanil and sufentanil. Preliminary pharmacokinetic profile in man
20. Characterization of the decrease of extracellular striatal dopamine induced by intrastriatal morphine administration
21. 5-enkephalin
22. Delta, mu, and kappa opioid receptor agonists inhibit dopamine overflow in rat neostriatal slices
23. Pharmacokinetics, pharmacodynamics, and rational opioid selection
24. 11C-raclopride
25. The effects of opioid peptides on dopamine release in the nucleus accumbens: An in vivo microdialysis study
26. 11C] raclopride
27. Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain
28. PET studies on the effects of aerobic exercise on human striatal dopamine release
29. Ethanol-induced increase in endogenous dopamine release may involve endogenous opiates
30. Morphine stimulation of mesolimbic and mesocortical but not nigrostriatal dopamine release in the rat as reflected by changes in 3-methoxytyramine levels
31. Facilitatory modulation of mesolimbic dopamine neuronal activity by a μ-opioid agonist and nicotine as examined with in vivo microdialysis